JP2013500329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013500329A5 JP2013500329A5 JP2012522328A JP2012522328A JP2013500329A5 JP 2013500329 A5 JP2013500329 A5 JP 2013500329A5 JP 2012522328 A JP2012522328 A JP 2012522328A JP 2012522328 A JP2012522328 A JP 2012522328A JP 2013500329 A5 JP2013500329 A5 JP 2013500329A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding
- composition
- particle
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000036639 antigens Human genes 0.000 claims 52
- 108091007433 antigens Proteins 0.000 claims 52
- 239000000427 antigen Substances 0.000 claims 51
- 239000000203 mixture Substances 0.000 claims 20
- 229920000642 polymer Polymers 0.000 claims 16
- 239000002245 particle Substances 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 201000008827 tuberculosis Diseases 0.000 claims 14
- 208000006454 hepatitis Diseases 0.000 claims 13
- 231100000283 hepatitis Toxicity 0.000 claims 13
- 230000028993 immune response Effects 0.000 claims 12
- 206010022000 influenza Diseases 0.000 claims 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 10
- 230000004927 fusion Effects 0.000 claims 10
- 150000007523 nucleic acids Chemical group 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- -1 MPT32 Proteins 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 230000003053 immunization Effects 0.000 claims 5
- 244000052769 pathogen Species 0.000 claims 5
- 230000001717 pathogenic effect Effects 0.000 claims 5
- 108010092821 Mycobacterium tuberculosis antigen 85A Proteins 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 101710088335 Diacylglycerol acyltransferase/mycolyltransferase Ag85A Proteins 0.000 claims 2
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 101150079015 esxB gene Proteins 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- OWMCODAXNFNLCU-UHFFFAOYSA-N 2-[[2-(1h-imidazol-5-yl)ethylamino]methyl]phenol Chemical compound OC1=CC=CC=C1CNCCC1=CN=CN1 OWMCODAXNFNLCU-UHFFFAOYSA-N 0.000 claims 1
- 101100008046 Caenorhabditis elegans cut-2 gene Proteins 0.000 claims 1
- 102000006303 Chaperonin 60 Human genes 0.000 claims 1
- 108010058432 Chaperonin 60 Proteins 0.000 claims 1
- 241000709687 Coxsackievirus Species 0.000 claims 1
- 101710088427 Diacylglycerol acyltransferase/mycolyltransferase Ag85C Proteins 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 101100291912 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) mpb64 gene Proteins 0.000 claims 1
- 101001043272 Mycobacterium tuberculosis (strain ATCC 25177 / H37Ra) Lipoprotein LpqH Proteins 0.000 claims 1
- 101000856404 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Carboxylesterase Culp1 Proteins 0.000 claims 1
- 101000941208 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Probable carboxylesterase Culp2 Proteins 0.000 claims 1
- 101100385666 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cut7 gene Proteins 0.000 claims 1
- 101100274117 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) groEL2 gene Proteins 0.000 claims 1
- 101100395578 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) hrp1 gene Proteins 0.000 claims 1
- 101150009192 PPE68 gene Proteins 0.000 claims 1
- 101150056612 PPIA gene Proteins 0.000 claims 1
- 101710181935 Phosphate-binding protein PstS 1 Proteins 0.000 claims 1
- 101710181937 Phosphate-binding protein PstS 2 Proteins 0.000 claims 1
- 101710181936 Phosphate-binding protein PstS 3 Proteins 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- 102000002932 Thiolase Human genes 0.000 claims 1
- 108060008225 Thiolase Proteins 0.000 claims 1
- 102000007362 alpha-Crystallins Human genes 0.000 claims 1
- 108010007908 alpha-Crystallins Proteins 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 101150027583 cfp32 gene Proteins 0.000 claims 1
- 101150001139 cfp6 gene Proteins 0.000 claims 1
- 239000012645 endogenous antigen Substances 0.000 claims 1
- 101150069551 esxH gene Proteins 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 101150007644 hspX gene Proteins 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 101150047914 mpt51 gene Proteins 0.000 claims 1
- 101150076681 mpt63 gene Proteins 0.000 claims 1
- 101150014428 mpt64 gene Proteins 0.000 claims 1
- 101150023079 mpt83 gene Proteins 0.000 claims 1
- 101150009453 mtc28 gene Proteins 0.000 claims 1
- 229960001005 tuberculin Drugs 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22934809P | 2009-07-29 | 2009-07-29 | |
| US22931809P | 2009-07-29 | 2009-07-29 | |
| US61/229,348 | 2009-07-29 | ||
| US61/229,318 | 2009-07-29 | ||
| PCT/IB2010/053465 WO2011013097A2 (en) | 2009-07-29 | 2010-07-29 | Polymer particles and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013500329A JP2013500329A (ja) | 2013-01-07 |
| JP2013500329A5 true JP2013500329A5 (https=) | 2013-09-05 |
Family
ID=43529777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522328A Pending JP2013500329A (ja) | 2009-07-29 | 2010-07-29 | ポリマー粒子およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20120201846A1 (https=) |
| EP (1) | EP2461822A4 (https=) |
| JP (1) | JP2013500329A (https=) |
| KR (1) | KR20140015127A (https=) |
| CN (2) | CN106421743A (https=) |
| AU (1) | AU2010277222A1 (https=) |
| CA (1) | CA2769645A1 (https=) |
| EA (1) | EA201290072A1 (https=) |
| SG (1) | SG178144A1 (https=) |
| WO (1) | WO2011013097A2 (https=) |
| ZA (1) | ZA201201482B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102180974B (zh) * | 2011-03-22 | 2013-12-11 | 兰州大学 | 一种结核杆菌融合蛋白及其制备方法和应用 |
| IN2014DN08675A (https=) * | 2012-04-16 | 2015-05-22 | Aeras Global Tb Vaccine Found | |
| WO2013190453A2 (en) * | 2012-06-18 | 2013-12-27 | Tracy Thompson | Compositions for separation methods |
| CN102716474B (zh) * | 2012-06-27 | 2013-10-16 | 中国人民解放军军事医学科学院微生物流行病研究所 | 蛋白Rh054_01780在抗黑龙江立克次体的免疫保护中的应用 |
| KR20150036593A (ko) * | 2012-07-24 | 2015-04-07 | 사노피 파스퇴르 | 뎅기열 바이러스 감염 예방용 백신 조성물 |
| US20140073022A1 (en) * | 2012-09-10 | 2014-03-13 | Wisconsin Alumni Research Foundation | Production of polyhydroxyalkanoates with a defined composition from an unrelated carbon source |
| SMT202100585T1 (it) * | 2014-02-04 | 2021-11-12 | Polybatics Ltd | Particelle di polimero e loro usi |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| GB2554206B (en) | 2015-03-06 | 2021-03-24 | Micromass Ltd | Spectrometric analysis of microbes |
| WO2016142692A1 (en) | 2015-03-06 | 2016-09-15 | Micromass Uk Limited | Spectrometric analysis |
| GB2552602B (en) * | 2015-03-06 | 2020-12-30 | Micromass Ltd | Desorption electrospray ionisation mass spectrometry ("DESI-MS") analysis of swabs |
| US11139156B2 (en) | 2015-03-06 | 2021-10-05 | Micromass Uk Limited | In vivo endoscopic tissue identification tool |
| CA2978042A1 (en) | 2015-03-06 | 2016-09-15 | Micromass Uk Limited | Tissue analysis by mass spectrometry or ion mobility spectrometry |
| CN112964625B (zh) | 2015-03-06 | 2024-06-07 | 英国质谱公司 | 细胞群体分析 |
| EP3726562B1 (en) | 2015-03-06 | 2023-12-20 | Micromass UK Limited | Ambient ionization mass spectrometry imaging platform for direct mapping from bulk tissue |
| BR112017028212A2 (pt) | 2015-07-03 | 2018-09-11 | Sanofi Pasteur | vacinação concomitante contra dengue e febre amarela |
| EP3443354B1 (en) | 2016-04-14 | 2025-08-20 | Micromass UK Limited | Spectrometric analysis of plants |
| BR112019004913B1 (pt) | 2016-09-16 | 2022-07-12 | Infectious Disease Research Institute | Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra |
| SG11202002933TA (en) | 2017-10-05 | 2020-04-29 | Sanofi Pasteur | Compositions for booster vaccination against dengu |
| KR102107519B1 (ko) * | 2018-06-25 | 2020-05-07 | 경상대학교산학협력단 | 브루셀라 어보투스 균주 유래의 InpB, Dps, AspC 및 Ndk 단백질을 유효성분으로 포함하는 브루셀라 감염증 예방 또는 치료용 백신 조성물 |
| KR102317403B1 (ko) * | 2019-01-28 | 2021-10-29 | 주식회사 바이오앱 | 당화된 Ag85A 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법 |
| CN109813884A (zh) * | 2019-03-25 | 2019-05-28 | 中国动物卫生与流行病学中心 | 一种牛结核病γ-干扰素快速检测制品 |
| CN110411907B (zh) * | 2019-06-19 | 2020-05-22 | 上海交通大学 | 植物叶片上亚微米颗粒物凝并效率测定方法、系统及介质 |
| GB201913716D0 (en) * | 2019-09-24 | 2019-11-06 | Imp College Innovations Ltd | Methods |
| JP7584763B2 (ja) * | 2020-06-04 | 2024-11-18 | 東亞合成株式会社 | 抗ウイルス性ペプチドおよびその利用 |
| CN117430664B (zh) * | 2023-10-24 | 2024-04-09 | 暨南大学附属第六医院(东莞市东部中心医院) | 一种甲型流感病毒t细胞抗原表位肽及其应用 |
| CN118085043B (zh) * | 2024-04-17 | 2024-07-19 | 成都康华生物制品股份有限公司 | 结核分枝杆菌多免疫原抗原、编码其的多核苷酸、应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3584866D1 (de) * | 1984-09-12 | 1992-01-23 | Chiron Corp | Hybridpartikel-immunogene. |
| US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| CA2285625C (en) * | 1997-04-02 | 2015-06-30 | Statens Serum Institut | Nucleic acid fragments and polypeptide fragments derived from m. tuberculosis |
| US6982085B2 (en) * | 1997-04-02 | 2006-01-03 | Statens Serum Institut | TB diagnostic based on antigens from M. tuberculosis |
| AUPR011700A0 (en) * | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
| AU2003242504A1 (en) * | 2002-07-13 | 2004-02-02 | Statens Serum Institut | Therapeutic tuberculosis vaccines |
| DE10240035A1 (de) * | 2002-08-30 | 2004-03-11 | Rehm, Bernd H.A., PD Dr.rer.nat. | Biogene Polyester-Partikel definierter Größe mit funktionalisierten Oberflächen:Herstellungsverfahren und pharmazeutische Zubereitungen, in denen diese enthalten sind |
| EP1631264B8 (en) * | 2003-06-02 | 2017-05-24 | GlaxoSmithKline Biologicals SA | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
| CA2612900C (en) * | 2005-06-23 | 2016-08-09 | Claus Aagaard | Improved tuberculosis vaccines |
| EP1929010B1 (en) * | 2005-09-27 | 2013-12-18 | PolyBatics Limited | Uses of polymer particles |
| CN100518821C (zh) * | 2006-09-14 | 2009-07-29 | 复旦大学 | Ag85B,ESAT-6的嵌合疫苗 |
-
2010
- 2010-07-29 CA CA2769645A patent/CA2769645A1/en not_active Abandoned
- 2010-07-29 CN CN201610287281.2A patent/CN106421743A/zh active Pending
- 2010-07-29 EA EA201290072A patent/EA201290072A1/ru unknown
- 2010-07-29 JP JP2012522328A patent/JP2013500329A/ja active Pending
- 2010-07-29 AU AU2010277222A patent/AU2010277222A1/en not_active Abandoned
- 2010-07-29 WO PCT/IB2010/053465 patent/WO2011013097A2/en not_active Ceased
- 2010-07-29 EP EP10803995.9A patent/EP2461822A4/en not_active Withdrawn
- 2010-07-29 US US13/387,739 patent/US20120201846A1/en not_active Abandoned
- 2010-07-29 SG SG2012006193A patent/SG178144A1/en unknown
- 2010-07-29 CN CN201080043214.7A patent/CN102573891B/zh not_active Expired - Fee Related
- 2010-07-29 KR KR1020127005296A patent/KR20140015127A/ko not_active Ceased
-
2012
- 2012-02-28 ZA ZA2012/01482A patent/ZA201201482B/en unknown
-
2015
- 2015-10-29 US US14/927,321 patent/US20160175419A1/en not_active Abandoned
-
2017
- 2017-03-08 US US15/453,073 patent/US20180015156A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013500329A5 (https=) | ||
| Coler et al. | The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial | |
| Zhu et al. | Tuberculosis vaccines: Opportunities and challenges | |
| Andersen | TB vaccines: progress and problems | |
| Gupta et al. | Current status of TB vaccines | |
| Orme | Vaccine development for tuberculosis: current progress | |
| Xin et al. | Subunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice | |
| US9795663B2 (en) | Compositions and methods | |
| ES2714383T3 (es) | Vacuna TB contra la tuberculosis para impedir la reactivación | |
| Geluk et al. | A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice | |
| Beresford et al. | Update on research and development pipeline: tuberculosis vaccines | |
| Haile et al. | Recent developments in tuberculosis vaccines | |
| US9315556B2 (en) | Compositions and methods | |
| US20080311159A1 (en) | Methods and Means for Diagnostics, Prevention and Treatment of Mycobacterium Infections and Tuberculosis Disease | |
| Méndez‐Samperio | Development of tuberculosis vaccines in clinical trials: Current status | |
| JP2012524733A5 (https=) | ||
| HUE031184T2 (en) | Modified tuberculosis antigens | |
| Hawkridge et al. | Prospects for a new, safer and more effective TB vaccine | |
| Reed et al. | Tuberculosis vaccine development; from mouse to man | |
| Tanner et al. | Serum indoleamine 2, 3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A | |
| Ginsberg et al. | TB vaccines in clinical development | |
| Safar et al. | COVID-19 vaccine development: What lessons can we learn from TB? | |
| JP2003519668A5 (https=) | ||
| Mustafa | Early secreted antigenic target of 6 kda-like proteins of mycobacterium tuberculosis: diagnostic and vaccine relevance | |
| Lu et al. | Immunogenicity and protective efficacy against murine tuberculosis of a prime‐boost regimen with BCG and a DNA vaccine expressing ESAT‐6 and Ag85A fusion protein |